TrialBMC cancer2018

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).

Nikolas von Bubnoff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.